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Divergent pathways mediate spine alterations and cell
death induced by amyloid-beta, wild-type tau, and R406W
tau
Abstract
Alzheimer's disease is characterized by synaptic alterations and neurodegeneration.
Histopathological hallmarks represent amyloid plaques composed of amyloid-beta (Abeta)
and neurofibrillary tangles containing hyperphosphorylated tau. To determine whether
synaptic changes and neurodegeneration share common pathways, we established an ex vivo
model using organotypic hippocampal slice cultures from amyloid precursor protein
transgenic mice combined with virus-mediated expression of EGFP-tagged tau constructs.
Confocal high-resolution imaging, algorithm-based evaluation of spines, and live imaging
were used to determine spine changes and neurodegeneration. We report that Abeta but not
tau induces spine loss and shifts spine shape from mushroom to stubby through a mechanism
involving NMDA receptor (NMDAR), calcineurin, and GSK-3beta activation. In contrast,
Abeta alone does not cause neurodegeneration but induces toxicity through phosphorylation
of wild-type (wt) tau in an NMDAR-dependent pathway. We show that GSK-3beta levels are
elevated in APP transgenic cultures and that inhibiting GSK-3beta activity or use of
phosphorylation-blocking tau mutations prevented Abeta-induced toxicity of tau. FTDP-17 tau
mutants are differentially affected by Abeta. While R406W tau shows increased toxicity in the
presence of Abeta, no change is observed with P301L tau. While blocking NMDAR activity
abolishes toxicity of both wt and R406W tau, the inhibition of GSK-3beta only protects against
toxicity of wt tau but not of R406W tau induced by Abeta. Tau aggregation does not correlate
with toxicity. We propose that Abeta-induced spine pathology and tau-dependent
neurodegeneration are mediated by divergent pathways downstream of NMDAR activation
and suggest that Abeta affects wt and R406W tau toxicity by different pathways downstream
of NMDAR activity.
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Divergent Pathways Mediate Spine Alterations and
Cell Death Induced by Amyloid-, Wild-Type Tau,
and R406W Tau
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Alzheimer’s disease is characterized by synaptic alterations and neurodegeneration. Histopathological hallmarks represent amyloid
plaques composed of amyloid- (A) and neurofibrillary tangles containing hyperphosphorylated tau. To determine whether synaptic
changes andneurodegeneration share commonpathways, we established an ex vivomodel using organotypic hippocampal slice cultures
from amyloid precursor protein transgenic mice combined with virus-mediated expression of EGFP-tagged tau constructs. Confocal
high-resolution imaging, algorithm-based evaluation of spines, and live imagingwere used to determine spine changes and neurodegen-
eration. We report that A but not tau induces spine loss and shifts spine shape from mushroom to stubby through a mechanism
involving NMDA receptor (NMDAR), calcineurin, and GSK-3 activation. In contrast, A alone does not cause neurodegeneration but
induces toxicity through phosphorylation of wild-type (wt) tau in an NMDAR-dependent pathway. We show that GSK-3 levels are
elevated in APP transgenic cultures and that inhibiting GSK-3 activity or use of phosphorylation-blocking tau mutations prevented
A-induced toxicity of tau. FTDP-17 tau mutants are differentially affected by A. While R406W tau shows increased toxicity in the
presence of A, no change is observed with P301L tau.While blocking NMDAR activity abolishes toxicity of both wt and R406W tau, the
inhibition ofGSK-3only protects against toxicity ofwt taubut not ofR406Wtau inducedbyA. Tau aggregationdoes not correlatewith
toxicity. We propose that A-induced spine pathology and tau-dependent neurodegeneration are mediated by divergent pathways
downstream of NMDAR activation and suggest that A affects wt and R406W tau toxicity by different pathways downstream of NMDAR
activity.
Introduction
Alzheimer’s disease (AD) is characterized by massive neurode-
generation and altered neuronal connectivity. Histopathological
hallmarks are the presence of extracellular amyloid plaques con-
sisting of aggregated A and intracellular neurofibrillary tangles
(NFTs) containing hyperphosphorylated tau. Most of AD cases
are spontaneous; however, familial AD (FAD)with an early onset
also occurs. FAD cases are due tomutations in the presenilin (PS)
genes 1 and 2 and in the APP gene, which increase generation of
the most amyloidogenic form of A, A42 (Steiner et al., 1999).
While mutations in the tau gene have been reported in fronto-
temporal dementia and parkinsonism linked to chromosome 17
(FTDP-17), in which they cause tau aggregation and neurodegen-
eration, no tau mutations have been identified in AD (Shahani and
Brandt, 2002). Based on this, the amyloid cascade hypothesis has
been developed (Hardy and Selkoe, 2002), in which changes in tau
are considered downstream of the A pathology.
Several studies showed that synaptic changes and neurode-
generation are separated temporally. However, whether both
share common pathways remains to be determined. Synaptic al-
terations as evidenced by a reduction in dendritic spine numbers
and changes in spine shape are an early event in AD and are
thought to be caused by soluble low-molecular-weight A oli-
gomers (Haass and Selkoe, 2007; Tackenberg et al., 2009). Tau
hyperphosphorylation and the formation of NFTs occur later.
While the amount of NFTs correlates with the degree of de-
mentia (Braak and Braak, 1991), little is known whether and
how tau affects spines and how tau and A interfere. Rapoport
et al. (2002) provided evidence for an essential role of tau in
A-induced cell death. Interestingly, a hyperphosphorylation-
mimicking tau mutant induced massive degeneration by itself
when overexpressed in neurons (Fath et al., 2002; Shahani et al.,
2006), suggesting that the extent of phosphorylation determines
tau toxicity. In agreementwith this, A can induce tau phosphor-
ylation at disease-relevant sites (Ferreira et al., 1997; Zheng et al.,
2002; Leschik et al., 2007). It has been shown that FTDP-17 tau
mutants can induce neurodegeneration in vivo (Lewis et al., 2000;
Miyasaka et al., 2005; Santacruz et al., 2005). However, themech-
anism by which the toxicity of wild-type (wt) tau and FTDP-17
tau mutants is induced and whether they share a common path-
way remain to be shown.
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To dissect the role of A and tau on spine changes and cell
death and to determine the mechanisms and signaling pathways
involved in both processes, we established an ex vivomodel based
on organotypic hippocampal slice cultures. Cultures were pre-
pared from transgenicmice expressingmutated APP (APPSDL) in
combination with virus-mediated expression of EGFP-coupled
wt tau and FTDP-17 mutated tau constructs. Confocal high-
resolution imaging and algorithm-based evaluation were used to
determine effects on spines. Cell death was visualized by live
imaging.
Our data indicate that spine changes and wt tau-mediated cell
death are both caused byA throughNMDAglutamate receptors
(NMDARs) and GSK-3 activation but involve different path-
ways. Furthermore, we show that the FTDP-17 mutant R406W
tau is also affected by A but in a GSK-3-independent pathway.
Materials andMethods
Animals. Heterozygous APPSDL transgenic C57BL/6 mice (Aventis
Pharma) and nontransgenic littermates (C57BL/6 mice; Charles River
Laboratories and Harlan Winkelmann) were used. APPSDL transgenic
mice express humanAPP695with three familial Alzheimer’s diseasemu-
tations in one construct, the Swedish (KM595/596NL), Dutch (E618Q),
and London (V642I)mutations, under the control of the platelet-derived
growth factor  promoter (Blanchard et al., 2003). All animals were
maintained and killed according to National Institutes of Health guide-
lines andGerman animal care regulations. Genotypingwas performed by
PCR fromDNA extracted frommouse tail using the following primers:
APP-forward, 5-GTAGCAGAGGAGGAAGAAGTG-3; and APP-
reverse, 5-CATGACCTGGGACATTCTC-3. Primers were purchased
from Biomers.
Materials. Chemicals were purchased from Sigma. Culture medium
and supplements were obtained from Sigma and Invitrogen, culture dishes
and plates from Nunc, and membrane culture inserts from Millipore.
Gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-
phenylglycine t-butyl ester (DAPT) was purchased fromMerck.
Sindbis virus constructs. Construction of virus was performed as de-
scribed previously (Shahani et al., 2006). The following virus constructs
were used for experiments: pSinRep5-EGFP, pSinRep5-EGFP-352wt tau,
pSinRep5-EGFP-352 pseudohyperphosphorylated (PHP) tau, pSinRep5-
EGFP-352 Ala tau, pSinRep5-EGFP-441 R406W tau, and pSinRep5-EGFP-
441 P301L tau. For PHP tau and Ala tau, 10 sites (Ser198, Ser199, Ser202,
Thr231, Ser235, Ser396, Ser404, Ser409, Ser413, and Ser422) were mutated
to glutamate and alanine, respectively (Eidenmu¨ller et al., 2001).
Organotypic hippocampal slice cultures and Sindbis virus infection. Or-
ganotypic hippocampal slice cultures were prepared and cultured ac-
cording to the study by Stoppini et al. (1991). In short, 6- to 7-d-old APP
transgenic and nontransgenic C57BL/6 mice were decapitated, brains
were removed, and both hippocampi were isolated and cut into 400-m-
thick slices by use of a McIllwain tissue chopper (Gabler). Slices were
cultured on Millicell culture plate inserts (0.4 m, Millipore) in six-well
plates containing 1 ml of culture medium (46%minimum essential me-
dium Eagle with HEPES modification, 25% basal medium with Earle’s
modification, 25% heat-inactivated horse serum, 2 mM glutamine, 0.6%
glucose, pH 7.2). Culture plates were kept at 37°C in a humidified atmo-
sphere containing 5%CO2. Slices were kept in culture for 12 d before the
experiments. Culture medium was exchanged every second or third day.
On day 11 culture medium was replaced by low-serum Nb-N1 medium
(94.5% neurobasal medium, 0.5% heat-inactivated horse serum, 2 mM
glutamine, 0.6% glucose, 1N1 supplement, pH 7.2). On day 12 in vitro
slice cultures were infected with Sindbis virus using a droplet method
(Shahani et al., 2006). For live imaging, culture plate inserts were trans-
ferred from six-well plates into glass-bottom dishes (MatTek). For spine
analysis, cultures were fixed at day 3 postinfection within six-well plates.
Slices were left attached to the culture plate membrane to preserve hip-
pocampal structure and rinsed with PBS. Slices were then fixed with 4%
paraformaldehyde in PBS containing 4% sucrose for 2 h at 4°C. After
being washed with PBS, cultures were mounted with Confocal matrix
(Micro-Tech-Lab) and coverslipped. To compare the expression levels of
EGFP-coupled tau constructs, the fluorescence intensity of infected neu-
rons was determined. Hippocampal slice cultures were infected with the
respective construct and fixed on day 3 postinfection. Confocal z-stack
images were acquired using identical microscope settings for the respec-
tive constructs. Using the ImageJ program, all optical sections were
scaled to 32-bit format and summed up. It was verified by software tools
that no pixels were saturated. Integrated fluorescence intensities were
determined relative to background fluorescence for 10 neurons per
construct.
Treatment of hippocampal slice cultures. The following inhibitors were
used to treat hippocampal slice cultures at the indicated concentrations
(in M): 0.5 and 1 -secretase inhibitor DAPT, 20 NMDAR antagonist
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), 1 cal-
cineurin inhibitor tacrolimus (FK-506), and 10 GSK-3 inhibitor
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD). For analy-
ses of effects on spines, all media were continuously supplemented with
the respective inhibitor. For assessment of cell death, inhibitors were
added only after replacing the culture medium with Nb-N1.
Antibodies. The following primary antibodies were used: phosphorylation-
independent tau antibody Tau-5 (mouse; PharMingen), phosphorylation-
dependent tau antibody PHF-1 (mouse; a generous gift from Peter
Davies, Albert Einstein College of Medicine, Bronx, NY), anti-synapto-
physin (mouse;Millipore), tubulin antibodyDM1A (mouse; Sigma), and
anti-GSK-3 and phospho-GSK-3/ (mouse; Cell Signaling Technol-
ogy). As secondary antibodies, cyanine 3 (Cy3)-coupled anti-mouse an-
tibody (Dianova) and peroxidase-conjugated anti-mouse antibodies
(Jackson ImmunoResearch) were used.
Immunohistochemistry. Infected hippocampal slices were left attached
on the insert membranes throughout the immunostaining protocol to
preserve the hippocampal structure. Immunostaining was performed
free floating to ensure penetration of antibodies inside the tissue. Slices
were first washed with PBS and fixed with 4% paraformaldehyde in PBS
containing 4% sucrose for 2 h at 4°C. After washing with PBS, slices were
treated with 1% Triton X-100 in PBS for 90 min and 50 mM ammonium
chloride for 45 min at room temperature. Slices were blocked with PBS
containing 5% fetal calf serum, 1% BSA, and 0.1% Triton X-100 at 4°C
overnight followed by incubation for 5 d at 4°C with primary antibodies
diluted in blocking solution. After being washed with PBS, slices were
incubated with Cy3-coupled anti-mouse antibody for 3 d at 4°C. The
slices were then washed in PBS, mounted in Confocal-Matrix (Micro-
Tech-Lab), and coverslipped.
Immunoblot analysis. Cultured hippocampal slices were harvested on
day 15, sonicated in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM
EDTA, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS, pH 8.0) contain-
ing protease inhibitors (1 mM PMSF, 10 g/ml each of leupeptin and
pepstatin, 1 mM EGTA) and phosphatase inhibitors (1 mM sodium or-
thovanadate, 20mM sodium fluoride, and 1mM sodiumpyrophosphate),
and centrifuged for 15min at 13,000 g at 4°C. The supernatant (lysate)
was collected, frozen, and stored at 80°C. Twenty percent of lysates
were subjected to SDS-PAGE and transferred to Immobilon-P (Milli-
pore) followed by immunoblotting with various antibodies. As second-
ary antibody, peroxidase-coupled anti-mouse antiserum was used.
Detection used enhanced chemiluminescence using SuperSignal West
Dura extended-duration substrate (Pierce) and was performed accord-
ing to the manufacturer’s protocol. Blots were quantified with Gel-Pro
Analyzer 4.0 (Media Cybernetics).
Sequential tau extraction.Tau solubility profiles were generated as pre-
viously described (Shahani et al., 2006) but without sonication, using the
following buffers: (1) high-salt buffer (750 mM NaCl, 50 mM Tris buffer,
pH 7.4), (2) 1% Triton in high-salt buffer, (3) RIPA buffer, (4) 2% SDS,
and (5) 70% formic acid (FA). All buffers were supplemented with phos-
phatase and protease inhibitors as described above. The same amounts of
extracts (20%) were loaded per lane and stained with Tau-5 antibody to
detect total tau.
Confocal live imaging and assessment of cell death. All images were
acquired on inverted Nikon confocal laser scanning microscope Eclipse
TE2000-Uusing argon laser (488 nm).Microscopewas equippedwith an
incubation chamber (Solent Scientific) generating a 37°C humidified
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atmosphere containing 5% CO2 to avoid neuronal death caused by low
temperature or pH shifts. Objectives used for live imaging were 4 (dry,
NA: 0.13) and 20 [dry, ELWD (extra long working distance), NA:
0.45]. Live imaging of infected hippocampal CA3 pyramidal neuronswas
performed over a period of 2–4 d postinfection. Image stacks were taken
at 1024 1024 pixels with pixel size of 0.62 m in the x and y directions
and 2.55 m steps in the z direction. The lowest laser intensity and pixel
dwell time possible were used to reduce phototoxicity. Maximum-
intensity projections of z sections were created using Nikon EZ-C1 3.0
software. For analysis of cell death the number of nondegenerated neu-
rons was counted on days 2, 3, and 4 for APP transgenic slices or non-
transgenic controls expressing different EGFP-coupled tau constructs.
Percentages of remaining neurons on days 3 and 4 were presented based
on the respective nontransgenic control (see Fig. 4) or relative to the
number of neurons at day 2 for the respective expressed construct (see
Fig. 5). Nondegenerated neurons were considered to have processes
without any varicosities and an intact cell body without any swellings.
For quantification, only pyramidal neurons with clear triangular shape
Figure 1. Spine density of EGFP- and EGFP-tau-expressing neurons in hippocampal slice cultures. A, Confocal image of a whole slice (left; scale bar, 300 m) after Sindbis virus-mediated
expression of EGFP-tau. Note that tau is expressed in every hippocampal subregionwith highest efficiency in CA3. Typicalmorphology of a CA3 pyramidal neuron (right; scale bar, 25m)with basal
dendrites in stratum oriens and apical dendrites in stratum radiatum region of the hippocampus. B, Representative high-resolution images of 20- to 30-m-long dendritic fragments of stratum
radiatum thick and thin and stratum oriens from CA1 and CA3 neurons after blind deconvolution. Scale bar, 5m. C, Spine density in hippocampal CA1 and CA3 neurons from APP transgenic and
nontransgenicmice after targeted expression of EGFP or EGFP-tau [n 19 (EGFP),n 10 (EGFP-tau)]. Spine density is strongly reduced onAPP transgenic background independent of the presence
of tau.D, Effect of-secretase inhibitorDAPTon spinedensity of EGFP-tau-expressingneurons fromAPP transgenic andnontransgenicmice.High-resolution image fromCA1 stratumradiatumthick
(left; scale bar, 5m). For quantitative analysis of spine density (right), data from CA1 and CA3 regions were pooled. DAPT (0.5M) completely abolished spine loss, whereas 1M DAPT had only
a partial albeit still significant effect (n41 for 0.5MDAPT treatment andn40 for 1MDAPT-treated anduntreated cultures). Analysis of spine density shows a reduction of spine loss byDAPT,
which is maximal at 0.5M. All values are shown as mean SEM (**p 0.01, ***p 0.001; one-tailed unpaired Student’s t test). DG, Dentate gyrus; str.or., stratum oriens; str.rad., stratum
radiatum; non tg., nontransgenic.
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Figure 2. Spinemorphology of EGFP- and EGFP-tau-expressing neurons in hippocampal slice cultures. A, Steps of image processing for detection and analysis of spines. Confocal raw imagewas
deconvoluted using 3D blind algorithm (Autodeblur). Medial axis extraction was performed by software 3DMA neuron for identification of dendritic backbone. Spine detection routine allowed
determining single spines, which were automatically analyzed for length and volume. Spine shape was classified by 3DMA neuron software to one of the following three types: “mushroom,”
“stubby,” or “thin.” B, Spine length in hippocampal CA1 and CA3 pyramidal neurons from APP transgenic and nontransgenic mice after targeted expression of EGFP or EGFP-tau. Spine length is
significantly reduced on APP transgenic background independent of tau. C, Spine volume in neurons fromAPP transgenic and nontransgenicmice after targeted expression of EGFP or EGFP-tau. No
difference is observed in spine volume between APP transgenic and nontransgenic cultures. D, Fraction of spines with different shape. Representative high-resolution images (left) show the
three different spine types for classification, namely, mushroom (left), stubby (middle), and thin (right). The fraction of mushroom spines is significantly decreased, while stubby spines
increase in CA1 and CA3 neurons from APP transgenic mice, independent of the presence of tau. E, Representative images of EGFP-labeled postsynaptic spines with (Figure legend continues.)
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and apical and basal dendrites were counted, whereas interneurons were
omitted. Infected CA3 regions had to have at least 15 or more infected
neurons to be taken into evaluation to avoid any bias due to low sample
number. Slices with a fewer number of neurons were disregarded.
Confocal imaging of fixed hippocampal slices and analysis of spine den-
sity. Confocal high-resolution imaging of spines was performed using
Nikon confocal laser scanningmicroscope Eclipse TE2000-Uwith a 60
objective (oil, NA: 1.4). Twenty- to 30-m-long fragments of different
dendritic subregions (stratum oriens and the proximal and medial part
of stratum radiatum thick and thin) of hippocampal CA1 and CA3 py-
ramidal neuronswere imagedwith voxel size of 0.08 0.08 0.25min
the x-y-z directions. Image size was adjusted according to the length and
shape of the imaged dendritic fragment. Image stacks were further pro-
cessed as described formorphological spine analysis. To determine spine
density, maximum projections were analyzed using NIH ImageJ soft-
ware. The length of the dendrite was measured, and spines were counted
as protrusions in the x and y axes. In addition, to visualize potential
colocalizations of postsynaptic spines with presynaptic boutons, some
slices were stained against synaptophysin. Images were recorded by se-
quential scanning using argon and helium–neon laser (544 nm).
Image processing and semiautomated analysis of spine morphology. Im-
age stacks (Nikon .ids files)were processed using 3Dblind deconvolution
(10–15 iterations, Autodeblur Software) to improve signal–noise ratio
and spatial resolution. Analysis of spine length, volume, and shape was
performed using 3DMA neuron software (Koh et al., 2002) which allows
algorithm-based, semiautomated evaluation of spine morphology.
Statistical analysis. For analysis of spine data or live imaging, statistical
evaluation was performed using a one-tailed, unpaired Student’s t test.
Data are shown as mean  SEM. For spine analysis, n is the number of
different analyzed images from at least four mice. For live imaging, n is
the number of analyzed hippocampal slices from at least four mice. For
statistical evaluation of Western blots, experiments were performed in
triplicate. Data are shown as mean  SD. Statistical analysis was per-
formed using paired Student’s t test. p values are as follows: *p  0.05,
**p 0.01, and ***p 0.001.
Results
A but not tau induces spine loss in hippocampal neurons
To determine the functional interaction of tau and A, EGFP-
tagged tau constructs were expressed in organotypic hippocam-
pal slices prepared fromAPP transgenic and nontransgenicmice.
For the experiments, Sindbis viral vectors, which allow a targeted
transient expression in different types of neurons, were used
(Ehrengruber et al., 1999; Shahani et al., 2006). Efficient infection
of neurons in all regions of the hippocampal slices was observed
from 2 to 5 d postinfection as evidenced by the intense EGFP
fluorescence (Fig. 1A, left). At higher magnification, single CA1
and CA3 neurons could be imaged and individual spines in dif-
ferent layers and dendritic segments visualized (Fig. 1A, right).
To determine differences in spine densities, dendritic seg-
ments of stratum radiatum thick and thin and stratum oriens of
EGFP-tau-expressing CA1 andCA3 neurons were imaged at high
resolution. In most segments, spine number appeared to be
reduced on an APP background compared with the nontrans-
genic control (Fig. 1B). No difference was seen in CA1 stratum
oriens and CA3 stratum radiatum thin. Quantification of
spine densities confirmed that spine number was significantly
reduced ( p  0.001) in CA1 and CA3 neurons from APP
transgenic mice (Fig. 1C). To determine a potential effect of
tau on spine number, neurons expressing EGFP-tau or EGFP
alone were compared. We did not observe any difference in
spine densities. This indicates that tau does not affect the
number of spines at our conditions.
To test whether spine number reduction was caused by mu-
tated APP or by A, the nontransition state -secretase inhibitor
DAPT was added to the cultures to block A generation (Dovey
et al., 2001). The presence of DAPT reduced spine loss in slices
fromAPP transgenic mice (Fig. 1D). Interestingly, 0.5MDAPT
completely abolished spine loss ( p 0.001), whereas 1MDAPT
had only a partial albeit still significant effect ( p 0.001), indi-
cating that the presence of A and not APP is responsible for
spine loss. It should however be noted that we cannot completely
exclude that also the APP intracellular domain (AICD) is in-
volved in pathologic processes, since DAPT treatment also pre-
vents AICD production.
The fact that higher concentrations of DAPT were less effec-
tivemay be due to increased toxicity of DAPT at 1M, which was
evident by an increased loss of neurons (data not shown).
Length is reduced and shape is changed in spines from APP
transgenic cultures
Evidence exists that memory formation results in structural plas-
ticity as seen in changes in the shape of spines (Bourne and Harris,
2007). To determine whether A induces alterations in spine
shape of EGFP- and EGFP-tau-expressing neurons, a computer-
assisted method was used which permits a semiautomated detec-
tion combined with a measurement of length and volume of
individual spines (Fig. 2A). Spine length was significantly re-
duced by 15% in APP transgenic slices in CA1 and CA3 neu-
rons (Fig. 2B). In contrast, no difference was observed in spine
volume betweenAPP transgenic and nontransgenic cultures (Fig.
2C). Interestingly, spine length was also reduced in regions in
which no loss of spines was observed (e.g., CA3 stratum radiatum
thin), indicating that A does not induce a selective loss of long
spines but generally reduces spine lengths (data not shown).
For further characterization of spine changes, spines were
classified into the three categories, namely, “mushroom,” “stubby,”
and “thin” (Peters and Kaiserman-Abramof, 1970), by using an
algorithm-based computer-assisted method (Fig. 2D). In the
CA1 and CA3 regions, the fraction of mushroom spines signifi-
cantly decreased, while stubby spines increased. Again, changes
were also observed in dendritic subregions in which no loss of
spines occurred, suggesting that mushroom spines do not vanish
but change to stubby shape. Importantly, no difference in spine
morphology was observed between EGFP- and EGFP-tau-expressing
neurons, confirming that tau does not affect spines.
To ascertain whether the remaining spines bear synapses, we
stained slices with an antibody against synaptophysin to label
presynaptic boutons (Fig. 2E). Mushroom as well as stubby
spines from nontransgenic and APP transgenic animals were in
close apposition with synaptophysin dots, suggesting the pres-
ence of functional synapses also after the change in spine shape.
Inhibition of NMDARs, calcineurin, or GSK-3 abolishes
A-induced spine alterations
It has been shown that A can bind to NMDARs (Lacor et al.,
2007) and that blockage of NMDAR activity reduces spine loss
that had been induced by addition of soluble A oligomers from
AD patients to slice cultures (Shankar et al., 2007). To determine
whether NMDARs are involved in A-mediated spine loss and
morphological changes, cultures from APP transgenic and non-
transgenic mice were treated with the NMDAR antagonist CPP.
We observed that CPP abolished the reduction in spine density in
4
(Figure legend continued.) synaptophysin-positive presynaptic boutons. All values are shown as
mean SEM (*p 0.05; **p 0.01; one-tailed unpaired Student’s t test). n 19 (EGFP),
n20 (EGFP-tau).mush.,Mushroomspine; stub., stubby spine; Synaptophys., synaptophysin.
Scale bars, 0.5m.
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cultures from APP transgenic mice (Fig.
3A). Interestingly, CPP slightly but signif-
icantly reduced spine density in nontrans-
genic controls by10%, while it strongly
increased spine density in APP transgenic
cultures ( p  0.001) to control levels.
CPP also abolished the difference between
spine length of APP transgenic and non-
transgenic animals (Fig. 3B). However, in
this case, this was due to a reduction of
spine length in control cultures rather
than to an increase in APP transgenic cul-
tures.We did not observe any influence of
CPP on the volume of the spines (Fig. 3B).
This is in agreement with our finding that
A did not affect spine volume (see
above). Analysis of spine shape showed no
effect of CPP on the fraction of the three
spine types in nontransgenic controls
(Fig. 3C). In APP transgenic cultures CPP
treatment increased the fraction of
mushroom-shaped spines and decreased
stubby spines to control levels. The increase
inmushroom-shaped spines reached signif-
icance in CA3 neurons ( p 0.02).
In addition to NMDAR activity, cal-
cineurin is thought to be involved in A-
mediated spine loss (Shankar et al., 2007).
Blocking calcineurin activity with tacroli-
mus (FK-506) increased spine density in
APP transgenic slices but reduced spine
density in controls (Fig. 3D) closely re-
sembling the effect of CPP. This suggests
that calcineurin is acting downstream of
NMDAR activation. Recently it has been
shown that A induces long-term depres-
sion (LTD) via activation of calcineurin
and GSK-3 (Li et al., 2009). To deter-
mine whether active GSK-3 is also in-
volved in A-mediated spine loss, we
treated the cultures with the GSK-3 in-
hibitor TDZD (Chen et al., 2007). TDZD
completely abolished A-induced spine
loss in the absence of any side effects
on control cultures (Fig. 3E), suggesting
that GSK-3 operates downstream of cal-
cineurin. Previously it has been shown
that during LTD calcineurin activates
protein phosphatase 1 (PP1), which in
turn activates GSK-3 (Mulkey et al.,
1994; Peineau et al., 2007) confirming the
presence of this pathway.
 induces wt tau toxicity by a
pathway involving NMDAR and
GSK-3 but not calcineurin
Evidence exists that both A and tau con-
tribute to the loss of neurons observed in
AD (Rapoport et al., 2002). To analyze a potential functional
interaction between tau and A, organotypic hippocampal slices
from transgenic and nontransgenic animals were infected with
virus expressing EGFP-wt tau or EGFP alone. Cell survival was
analyzed by live imaging of neurons in the CA3 region. The CA3
region was chosen, since generallymore neurons were infected in
this region (Fig. 1A, left) and since previous results indicated that
the CA3 region was more susceptible to tau-mediated degenera-
tion than the CA1 region (Shahani et al., 2006). For evaluation,
same regions were imaged at days 2, 3, and 4 postinfection (Fig.
Figure 3. Effect of NMDAR antagonist CPP, calcineurin inhibitor FK-506, and GSK-3 inhibitor TDZD on spines in hippocampal
slice cultures.A, Spinedensity in EGFP-expressinghippocampal CA1andCA3neurons fromAPP transgenic andnontransgenicmice
without treatment (top) and after treatment with 20M CPP (bottom). Representative high-resolution images of 20- to 30-m-
long dendritic fragments of stratum radiatum thick from CA1 and CA3 neurons after blind deconvolution (left) and quantification
of spine density (right) are shown. In untreated slices from APP transgenic mice, spine density is strongly reduced compared with
nontransgenic slices (n10). After CPP treatment, spine density does not differ betweenAPP transgenic andnontransgenic slices
[n 18 (nontransgenic), n 17 (APP transgenic)]. Compared with untreated cultures (Fig. 1C) spine density is reduced on
nontransgenic backgroundand increased for APP transgenicmice.B, Spine length and volumeafter treatmentwith 20MCPP.No
difference in spine length is observed between APP transgenic and nontransgenic controls after CPP treatment. Compared with
untreated cultures, spine length is significantly reduced in controls. CPP has no effect on spine volume. C, Fraction of spines with
different shapes after CPP treatment. CPP increases the fraction of mushroom-shaped spines in APP transgenic cultures to control
levels.D, Representative images of dendritic fragments after treatmentwith 1MFK-506 (left) andquantification of spine density
(right). FK-506 increases spine density in APP transgenic sliceswhile reducing spine density in controls (n 14). E, Representative
images of dendritic fragments after treatmentwith 10M TDZD (left) and quantification of spine density (right). TDZD completely
abolishes spine loss in APP transgenic cultures and does not affect controls (n 12). ( #p 0.05 and ##p 0.01 indicate a
significant decrease and p 0.05; p 0.001 a significant increase compared with untreated cultures; mean SEM;
one-tailed unpaired Student’s t test). mush., Mushroom spine; stub., stubby spine; str.rad., stratum radiatum. Scale bars, 5m.
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4A) and intact neurons according tomor-
phological criteria were counted (see Ma-
terials and Methods for details). After
expression of EGFP-wt tau in nontrans-
genic cultures, most neurons survived
(Fig. 4A, left). In contrast, a massive de-
generation of neurons was observed after
EGFP-tau expression on APP transgenic
background. Degenerationwas evident by
a complete loss of neurons or the develop-
ment of a ballooned phenotype. Quantifi-
cation revealed a progressive loss of
neurons from 30% (day 3) to 60% (day 4)
( p 0.001) (Fig. 4B). In contrast, no dif-
ference was observed between APP trans-
genic and nontransgenic cultures after
expression of EGFP alone. Preventing
	 formation by treatment with the
-secretase inhibitor DAPT abolished
tau toxicity in APP transgenic cultures,
indicating that the presence of A is re-
sponsible for induction of tau toxicity.
To determine whether NMDAR, cal-
cineurin, and GSK-3 activation is
also involved in A-induced tau toxicity,
cultures were treated with the respective
inhibitors. CPP and TDZD treatment
abolished neuronal loss, whereas FK-506
had no effect (Fig. 4A,B).
To specify the effect of A on GSK-3,
Western blots were performed to deter-
mine the amounts of total and phosphor-
ylated (inactive) GSK-3 in lysates of
hippocampal slices (Fig. 4C, left). In APP
transgenic cultures the expression level of
GSK-3 was significantly increased by
80% (Fig. 4C, top right). Application of
TDZD caused a significant increase in
phosphorylated (inactive) GSK-3 on
APP transgenic background by 70%
(Fig. 4C, bottom right). The data suggest
that TDZD reduces the amount of active
GSK-3, which is produced by the in-
creased expression in APP transgenic cul-
tures. Together, the data indicate that
neurodegeneration is induced by A and
that A requires tau. Tau toxicity is in-
duced by a cascade involving NMDARs
and GSK-3 activation but not cal-
cineurin. The fact that NMDAR blockage
prevents neurodegeneration makes it un-
likely that AICD is involved in the patho-
logic processes in our system.
Figure 4. Effect of CPP, FK-506, and TDZD on the survival of wt tau-expressing neurons in the CA3 region of hippocampal slice
cultures. A, Live imaging of EGFP-tau-expressing CA3 neurons from nontransgenic and APP transgenic cultures from day 2 to day
4 postinfection after treatment as indicated. Scale bars, 25m. B, Quantification of cell loss on day 3 (top) and day 4 (bottom)
postinfection standardized to the respective nontransgenic control. The fraction of nondegenerated neurons as determined by
morphological criteria is shown. No difference in cell survival between APP transgenic and nontransgenic cultures expressing only
EGFP is observed. EGFP-tau expression results in progressive loss of neurons in cultures fromAPP transgenicmice. Treatment with
-secretase inhibitor DAPT, NMDAR antagonist CPP, or GSK-3 inhibitor TDZD but not calcineurin inhibitor FK-506 abolishes
tau-dependent neuronal loss on APP transgenic background. C, Effect of TDZD on expression and phosphorylation of GSK-3 in
APP and nontransgenic slices as determined byWestern blot analysis (left). Quantification of total GSK-3 relative to tubulin (top
right) and of phospho-GSK-3 relative to total GSK-3 (bottom, right). Expression of GSK-3 is increased inAPP transgenic slices.
TDZD treatment increases phospho-GSK-3 (inactive GSK-3) levels. The experiment was performed in triplicate. Values are
4
shown as mean SEM (B) and mean SD (C) with *p
0.05, ***p 0.001; Student’s t test [n 11 (EGFP), n 8
(EGFP-tau, nontransgenic), n  12 (EGFP-tau, APP trans-
genic), n  8 (DAPT, nontransgenic), n  12 (DAPT, APP
transgenic), n 9 (FK-506, nontransgenic), n 10 (FK-506,
APP transgenic), n 9 (TDZD)].
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Disease-relevant tau mutants
differentially induce cell death in
combination with A
It has been shown that overexpression of
FTDP-17 tau mutants such as P301L and
R406W in transgenicmice leads to the de-
velopment of NFTs and neuronal degen-
eration (Lewis et al., 2000; Zhang et al.,
2004). The accumulated tau was phos-
phorylated at disease-relevant residues
(Ikeda et al., 2005). Combination with
APP or A increased tangle formation in
P301Lmice (Lewis et al., 2000; Go¨tz et al.,
2001). To analyze the effect of tau phos-
phorylation and tau mutations in combi-
nation with A, EGFP-tagged PHP tau, a
less phosphorylatable tau construct (Ala
tau), and the two FDTP-17 mutants
P301L and R406W tau were prepared in
Sindbis virus (Fig. 5A). To determine the
effect of the APP transgene on phosphor-
ylation of the different tau mutants, slices
from APP transgenic and nontransgenic
mice were infected with the constructs
and quantitative Western blot analysis
was performed.Detection used the PHF-1
antibody that reacts with a phosphory-
lated epitope at S396 and S404, which is
also phosphorylated by GSK-3 (Shahani
and Brandt, 2002). Phosphorylation of wt
tau at the PHF-1 site was significantly in-
creased by 25% on APP transgenic
background compared with nontrans-
genic control indicating that A caused
increased phosphorylation of wt tau (Fig.
5B). Compared with wt tau, both FTDP-17
mutants showed a drastically reduced
phosphorylation on nontransgenic back-
ground at the PHF-1 site by 65 and 45%
(R406W tau and P301L, respectively).
More importantly, A did not affect the
phosphorylation level of both mutants,
suggesting that A differentially affects
phosphorylation of wt tau and FTDP-17
mutants. As expected, PHP tau and Ala tau
were not immunoreactive with PHF-1,
since the epitope had been mutated to glu-
tamate and alanine, respectively.
Survival of neurons in the CA3 region
expressing tau mutants was determined
by live imaging (Fig. 5C). Expression of
PHP tau on a nontransgenic background
resulted in a progressive loss of neurons
compared with wt tau (40% at day 3 and
50% at day 4). In contrast to wt tau, loss of
neurons was not increased after expres-
sion of PHP tau on an APP background.
Expression of the less phosphorylatable
Ala tau construct did not induce cell loss
on either nontransgenic or APP trans-
genic background. This indicates that
increased phosphorylation as mimicked
by our pseudohyperphosphorylated con-
Figure 5. Survival of hippocampal CA3 neurons after expression of disease-relevant tau constructs in hippocampal slice
cultures. A, Schematic representation of the primary structure of the used tau constructs. B, Western blot showing expres-
sion of the different tau constructs (Tau-5) and phosphorylation at the PHF-1 site. Quantification of PHF-1 signal relative to
total tau shows increased phosphorylation of wt tau on APP transgenic background. Phosphorylation of R406W tau and
P301L tau is reduced compared with wt tau by 65 and 44%, respectively. In contrast to wt tau, phosphorylation of R406W
tau and P301L tau is not increased on APP background. Expression levels of the different constructs varied due to different
numbers of infected cells. Experiment was performed in triplicate. C, Live imaging of hippocampal CA3 neurons from
nontransgenic (top) or APP transgenic mice (bottom) expressing EGFP-tagged tau mutants from day 2 to day 4 postinfec-
tion. Scale bars, 25 m. D, Quantification of cell loss on day 3 (left) and day 4 (right). Cell numbers on days 3 and 4 are
shown relative to day 2 (set as 100%) for the respective construct. Strong and progressive cell death is seen for cells
expressing PHP tau, independent of transgenic background. Expression of R406W tau causes increased neuronal loss in
nontransgenic controls on day 4 compared with wt tau expression and strongly induces cell death in APP transgenic
cultures. No difference is seen in Ala tau- and P301L-expressing neurons in APP transgenic cultures and nontransgenic
controls. Values are shown as mean SD (B) and mean SEM (D) with *p 0.05 and ***p 0.001; Student’s t test
[n 8 (wt tau, nontransgenic), n 12 (wt tau, APP transgenic), n 8 (Ala tau), n 14 (PHP tau, nontransgenic), n
12 (PHP tau, APP transgenic), n  8 (R406W tau), n  13 (P301L tau, nontransgenic), n  10 (P301L tau, APP
transgenic)].
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struct is required for the toxic properties of tau in the presence of
A. Interestingly, expression of the two FTDP-17 mutants,
P301L and R406W tau, differentially affected the survival of neu-
rons dependent on the presence of A.While neuronal death was
significantly increased after expression of R406W tau on an APP
background ( p  0.001), no change was observed after expres-
sion of P301L. In addition, significant neuron loss was observed
at day 4 with R406W tau (20% loss compared with wt tau; p 
0.01) but not with P301L tau in nontransgenic controls (Fig. 5D).
Thus, although both mutations induce a
tauopathy in patients, the mechanism by
which they affect neuronal survival ap-
pears to differ, as evidenced by their dif-
ferential effect in the presence and
absence of A. To control for similar ex-
pression levels of the different constructs,
the amounts of wt tau, R406W tau, and
P301L tau in single neurons were deter-
mined by measuring the fluorescence in-
tensity of neurons after infection with the
respective EGFP-tau construct. Three
days postinfection mean fluorescence in-
tensities of 101  10 and 101  9% for
R406W tau and P301L tau, respectively,
were observed in nontransgenic controls
(wt tau set to 100%; n 10 per construct).
In APP transgenic slices, fluorescence in-
tensities of 97 7, 96 10, and 101 9%
were observed for wt tau, R406W tau, and
P301L tau, respectively. The data confirm
that the differential effects are caused by
different toxic properties of the respective
tau constructs rather than by different ex-
pression levels.
The data indicate that phosphoryla-
tion of wt tau is required for A-induced
cell death. Mimicking high phosphoryla-
tion using PHP tau abolishes the require-
ment for A. The FTDP-17 tau mutant
R406W shows some neurotoxicity by it-
self. Interestingly, the increased toxicity
of R406W tau in APP transgenic slices is
not paralleled by increased phosphory-
lation at the PHF-1 site, suggesting that
the mechanisms by which A confers
toxicity to tau are different for wt tau
and R406W tau.
 increases R406W tau toxicity by a
pathway involving NMDARs but
independent of GSK-3 or calcineurin
Our data suggest that A affects wt tau
and the FTDP-17 mutant R406W tau by
different mechanisms. To determine the
signal transduction pathway involved in
A-induced R406W tau toxicity, cell sur-
vival was analyzed for CA3 neurons ex-
pressing R406W tau in APP transgenic or
nontransgenic cultures treated with CPP,
FK-506, or TDZD (Fig. 6A). Blocking
NMDAR activity with CPP abolished A-
induced toxicity of R406W tau, whereas
FK-506 treatment failed to show a protec-
tive effect. This indicates that both wt tau and R406W tau
toxicity is mediated by NMDARs but not calcineurin. In con-
trast, treatment with TDZD did not affect cell survival on an
APP transgenic background in R406W tau-expressing cells, while
it was protective inwt tau-expressing neurons (compare Figs. 6B,
right, 4B, right). This suggests that GSK-3 is not involved in
A-induced R406W tau toxicity. Thus, the data indicate that A
induces R406W tau toxicity by a different pathway than it does
for wt tau.
Figure 6. Effect of CPP, FK-506, and TDZD on the survival of R406W tau-expressing neurons in the CA3 region of hippocampal
slice cultures. A, Live imaging of EGFP-R406W tau-expressing CA3 neurons from nontransgenic and APP transgenic cultures from
day 2 to day 4 postinfection after treatment as indicated. Scale bars, 25m. B, Quantification of cell loss on day 3 (top) and day 4
(bottom) postinfection standardized to the respective nontransgenic control. The fraction of nondegenerated neurons as deter-
mined bymorphological criteria is shown. Neuronal loss is increased after expression of R406W tau on APP transgenic background
comparedwith nontransgenic control. This effect is abolished by treating cultureswith CPP but notwith FK-506 or TDZD. Note that
treatment with FK-506 and TDZD also decreased neuronal survival of the controls. All values are shown as mean SEM with
***p 0.001; one-tailed unpaired Student’s t test; [n 8 (R406W tau, untreated), n 9 (R406W tau, nontransgenic, CPP), n
12 (R406W tau, APP transgenic, CPP), n 8 (R406W tau, nontransgenic, FK-506), n 9 (R406W tau, APP transgenic, FK-506),
n 9 (R406W tau, TDZD)].
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The solubility profiles of wt, R406W, and P301L tau do not
correlate with toxicity
To determine whether the toxicity of the different tau constructs
correlates with potential tau aggregation, the solubility profiles of
wt tau, R406W tau, and P301L tau were analyzed by a sequential
extraction protocol using buffers of increasing stringency (Fig.
7). With all constructs and at every condition, tau was not de-
tected in the FA fraction, implicating the absence of highly insol-
uble tau species. Compared with wt tau, both FTDP-17 mutants
showed a slightly reduced solubility on a nontransgenic back-
ground (wt tau, 58%; R406W tau, 45%; P301L tau, 42% in the
soluble fraction), which was mainly evident by an increased
amount of tau in the SDS fraction. Interestingly, on anAPP trans-
genic background, solubility of all constructs was increased by
10% for wt tau and by 16 and 22% for R406W tau and P301L tau,
respectively. Thus, R406W tau and P301L tau do not show dif-
ferences in their aggregation propensities, although they strongly
differ in their toxic properties in the presence and absence of A
as described above (Fig. 5). This indicates that the solubility of wt
tau, R406W tau, and P301L tau does not correlate with toxicity in
our experiments.
Discussion
We have established an ex vivo model of AD using organotypic
hippocampal slice cultures fromAPPSDL transgenicmice in com-
bination with Sindbis virus-mediated expression of fluorescent
labeled tau constructs. Detailed spine analysis was performed by
algorithm-based evaluation of high-resolution confocal images
of dendritic segments of CA1 and CA3 pyramidal neurons. Neu-
ronal survival was determined by live imaging. This approach
permits analysis of the relation between cell death and synaptic
changes and the interaction between A and tau pathology. In
addition, it permits determination of signal transduction mech-
anisms that are involved in each of these pathways in an experi-
mentally well accessible system.
Previously it has been shown that senile plaques and A oli-
gomers reduce spine density in vivo and in slice cultures (Tack-
enberg et al., 2009). In agreement with this, we observed that
spine densitywas strongly reduced inAPPSDL transgenic cultures.
Interestingly, spines were not affected by tau expression. Spine
loss was abolished in the presence of the -secretase inhibitor
DAPT, suggesting that the effect on spines was due to A. Since
APPSDLmice do not develop plaques before the age of 18months
(Blanchard et al., 2003), spine loss was induced by soluble A in
our experiments. It was previously reported that addition of sol-
uble A to slice cultures resulted in increased spine length but did
not affect spine head diameter (Shrestha et al., 2006). However, a
detailed analysis of changes in spine types caused by A had not
been performed. In nontransgenic cultures, algorithm-based cal-
culation revealed50% mushroom, 40% stubby, and 10% thin
spines. These numbers closely reflect the distribution in similar
cultures that have been evaluated manually by measurements of
spine length and head diameter (Zagrebelsky et al., 2005). We
observed a reduced percentage of mushroom spines and an in-
crease in the fraction of stubby spines in neurons fromAPP trans-
genic mice. The change in spine shape was also observed in
dendritic subregions in which no spine loss occurred. This indi-
cates a transition frommushroom to stubby spines but no selec-
tive loss of mushroom spines. The morphological change is
associated with a reduction in mean spine length, suggesting that
A causes spine retraction. Interestingly, spine volume was not
affected. Staining of presynaptic boutons against synaptophysin
showed that mushroom and stubby spines from nontransgenic
and APP transgenic animals were in close apposition with synap-
tophysin dots. While this is suggestive for the presence of func-
tional synapses also after the change in spine shape it cannot be
excluded that the strength of synaptic transmission is affected.
Cell survival was determined by live imaging of infected CA3
pyramidal neurons. We did not observe a difference between
nontransgenic andAPPSDL transgenic cultures after expression of
EGFP indicating that A alone is not neurotoxic. In contrast, we
observed massive neurodegeneration after expression of EGFP-wt
tau in APP transgenic cultures compared with nontransgenic
controls, whichwas prevented byDAPT. This indicates that tau is
essential for A-inducedneurodegeneration,which is in agreement
Figure 7. Sequential extraction of wt, R406W, and P301L tau from hippocampal slice cul-
tures. Tau solubility profiles from lysates of infected nontransgenic and APP transgenic slices.
The extraction was performed using the following buffers of increasing stringency: high salt
(HS), 1% Triton (Trit.), RIPA, 2% SDS, and 70% FA. The majority of wt tau protein was found in
the HS fraction. In nontransgenic controls, R406W tau and P301L tau is increased in the insol-
uble fraction to 54–57% compared with wt tau (42%). On the APP transgenic background the
insoluble tau fraction is decreased for all constructs (33–39%). Equal amounts of lysates from
each extraction step were loaded and stained with Tau-5 antibody against total tau.
Figure 8. Schematic representation showing the proposed pathways that mediate spine
pathology and tau-dependent cell death. The formation of A is central, since blocking A
production by treatment with the-secretase inhibitor DAPT abolishes spine changes and the
induction of tau toxicity. NMDAR activity is required for both induction of spine alterations and
A-induced tau toxicity, since blocking NMDAR activity with CPP abolishes both pathologies.
Abutnot tau causes loss of spines, reductionof spine length, andalterations in spine shape, as
evidenced by a shift from mushroom to stubby spines. In contrast, A alone is not neurotoxic
but requires tau to induce cell death. GSK-3 is activated by A and participates in both
cascades but calcineurin is operating only in mediating spine changes. Within spines, cal-
cineurin is upstream of GSK-3, since calcineurin inhibition mimics the effect of the NMDAR
antagonist CPP. In the soma, A activates GSK-3 independent of calcineurin, which is essen-
tial for the induction of wt tau toxicity, since blocking GSK-3 activity abolishes cell death
caused bywt tau in APP transgenic cultures, whereas calcineurin inhibition has no effect on cell
survival. In contrast, induction of R406W tau toxicity by A is GSK-3 independent, suggesting
that A affects R406W tau by a differentmechanism. Continuous lines show direct effects, and
dashed lines show indirect effects with potential intermediate steps.
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with studies using dissociated hippocampal cultures (Rapoport et
al., 2002). This raises the question by which mechanism A
induces tau toxicity. We showed that phosphorylation of wt
tau is increased on APP transgenic background at the PHF-1
site (phosphorylated S396 and S404), an epitope that is among
others phosphorylated by GSK-3 (Shahani and Brandt, 2002). In
agreement, expression levels of GSK-3 were increased in APP
transgenic cultures. Increased expression or activation of several tau
kinases including GSK-3 has already been reported in AD
(Blurton-Jones and Laferla, 2006). Mutation of 10 of the major
phosphorylation sites to alanine to prevent phosphorylation abol-
ished increased toxicity in the presence of A. In turn, PHP tau in
which the same sites were mutated to glutamate to mimic a perma-
nent hyperphosphorylation showed toxicity even on a nontrans-
genic background supporting that increased phosphorylation at
disease-relevant sites can confer toxicity to tau.
Many mouse models for AD have been developed by express-
ing tau with FTDP-17 mutations in combination with mutated
APP or PS1. However, no FAD cases were reported in which tau
is mutated. Thus, it is important to compare the effect of A on
wt tau and FTDP-17 tau mutants to determine whether these
provide a valid model for AD pathology. We determined the
behavior of two FTDP-17 mutants that have been frequently
used.We observed that R406W tau is more toxic than wt tau on a
nontransgenic background and becomes highly toxic in the pres-
ence of A. In contrast, P301L tau did not show any toxicity
neither in nontransgenic controls nor on an APP background. In
contrast to wt tau, the increased toxicity of R406W tau in APP
transgenic slices is not paralleled by increased phosphorylation at
the PHF-1 site, suggesting that the mechanism how A confers
toxicity to tau is different for wt tau and R406W tau. This makes
it questionable to use FTDP-17 taumutants in combination with
APP or A as a model for neurodegeneration in AD.
It is unknown whether soluble or aggregated tau causes neu-
rodegeneration.We determined the aggregation propensity of wt
tau, R406W tau, and P301L tau in the presence or absence of A.
Interestingly, A increased the solubility of all constructs. R406W
tau and P301L tau did not show differences in their aggregation
propensity although they strongly differ in their toxic properties
in the presence and absence of A. Thus, our data indicate that
the solubility of wt tau, R406W tau, and P301L tau does not
correlate with toxicity and suggests that tau-dependent neurode-
generation occurs in the absence of major tau aggregates. This is
in agreement with the observation that tau-dependent neurode-
generation occurred in a Drosophilamodel without NFT forma-
tion (Wittmann et al., 2001) and that in a zebrafish model
degeneration preceded tangle formation (Paquet et al., 2009). In
a mouse model, neuron number stabilized and memory recov-
ered after tau suppression despite continuous accumulation of
NFTs (Santacruz et al., 2005).
Our approach permits to investigate the signal transduction
pathways involved in mediating both spine changes and cell
death (Fig. 8). We show that blocking A production by treat-
ment with the -secretase inhibitor DAPT abolished both spine
changes and the induction of tau toxicity. This indicates that the
generation of A is upstream of both processes, which supports
the amyloid cascade hypothesis. It has been shown previously
that soluble A oligomers can bind to or nearNMDARs (Lacor et
al., 2007). Shankar et al. (2007) have shown that blockade of
NMDARs abolished spine loss, which had been induced by the
acute addition of soluble A. A induced LTD via activation of
calcineurin and GSK-3 (Li et al., 2009). This raises the question
whether NMDARs, calcineurin, and GSK-3 are also involved in
mediating spine changes inAPPSDL cultures.We found that treat-
ment with NMDAR antagonist CPP, calcineurin inhibitor FK-
506, and GSK-3 inhibitor TDZD abolished A-mediated spine
loss. Since the effect of FK-506 closely resembled the effect of CPP
including a reduction of spine number in controls, GSK-3 ap-
pears to be downstream of calcineurin, which is consistent with
the finding that GSK-3 activity is regulated, among others, by
calcineurin (Lee et al., 2005). Thus, A induces a cascade involv-
ing NMDAR, calcineurin, and GSK-3 activation, which alters
neuronal connectivity as observed in AD. It has been suggested
that A influences spines by mimicking an LTD-like partial
blockade of NMDARs followed by activation of cofilin and cal-
cineurin which finally leads to degradation of the actin cytoskel-
eton within the spine (Shankar et al., 2007). A complete blockade
of NMDAR activity by NMDAR antagonist CPP may therefore
prevent the induction of downstream cascades and protect
against A-induced spine alterations.
We could show for the first time that the induction of tau
toxicity by A is also NMDAR dependent since blockade of
NMDARs abolished cell death mediated by wt tau or R406W tau
in APP transgenic cultures. In contrast to the cascade causing
spine loss, the induction of tau toxicity is not calcineurin depen-
dent. Blocking GSK-3 prevented toxicity of wt tau but not
R406W tau on APP transgenic background. This is in agreement
with our finding that phosphorylation of R406W tau is not
increased at the PHF-1 site in APP transgenic cultures and
further supports that wt tau and R406W tau are differentially
affected by A.
Although both spine alterations and cell death are mediated
by NMDARs, the downstream cascades substantially differ, since
a blockade of calcineurin prevented spine loss but not cell death.
We hypothesize that both cascades occur in different cellular
compartments. A may cause spine changes by inducing a cas-
cade involving NMDARs, calcineurin, and GSK-3 within the
spine itself while inducing a calcineurin-independent cascade in-
volving NMDARs and GSK3 at the soma, which causes wt tau
phosphorylation and cell death.
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